



## Drug Resistance and Novel Targets for Cancer Therapy—Second Edition

Guest Editors:

**Dr. Bruno Kaufmann Robbs**

Instituto de Saúde de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Brazil

**Dr. Fernando de Carvalho da Silva**

Departamento de Química Orgânica, Instituto de Química, Universidade Federal Fluminense, Niterói 24020-141, RJ, Brazil

Deadline for manuscript submissions:

**31 July 2024**

### Message from the Guest Editors

Drug resistance is a complex phenomenon resulting from one or more mechanisms which render cells resistant to anticancer drugs. Molecular hallmarks of cancer and therapeutics against drug resistance mechanisms are the leading targets for cancer treatment. Molecular targeted therapy is gaining attraction due to its specificity to cancer while sparing normal cells. Despite this, drug resistance still represents a major obstacle that limits sustained clinical benefits not only to targeted cancer therapies, but also conventional chemotherapy.

In this context, we are proposing a new Special Issue encompassing these two major molecular pathways involved in cancer treatment such as the determinations of new cancer related molecular targets, development of drugs that block them and drugs that aims resistance to treatment. We invite innovative research papers and review articles discussing new molecular targets or anticancer drugs. We encourage articles related, but not restricted to Apoptosis Induction, Proliferative Signaling, Angiogenesis, Metastasis, Immune Checkpoint, Tumor Vaccine Related Targets, Chimeric Antigen Receptor T-Cell or their possible drug resistance mechanisms.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)